MicroStockProfit.com announces an investment report featuring ARIAD Pharmaceuticals Inc. (Nasdaq:ARIA). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
ARIAD Pharmaceuticals Inc. (ARIA) is a biopharmaceutical company focused on the discovery and development of drugs to provide therapeutic intervention in treating human diseases at the cellular level. The Company's lead cancer product candidate, ridaforolimus, is an internally discovered, potent inhibitor of the protein mTOR. mTOR acts as a central regulator of protein synthesis, cell proliferation, cell cycle progression and cell survival. Its second product candidate, AP24534, is an investigational, pan BCR-ABL inhibitor that has potential applications in various hematological cancers and solid tumors and is wholly owned by the Company. Its third product candidate, AP26113, is an investigational anaplastic lymphoma kinase (ALK), inhibitor that has the potential to regulate multiple cancer pathways and to be used in the treatment of certain patients with various cancers, including non-small cell lung cancer, lymphoma and neuroblastoma.
Message Board Search for ARIA: http://www.boardcentral.com/boards/ARIA
In the report, the analyst notes:
"For the fourth quarter ended December 31, 2009, ARIA reported a net loss of $18.0 million, or $0.17 per share, compared to a net loss of $16.8 million, or $0.24 per share, for the same period in 2008. For the full year ended December 31, 2009, ARIA reported a net loss of $80.0 million, or $0.86 per share, compared to a net loss of $71.1 million, or $1.02 per share for the same period in 2008.
"ARIA recently announced that it has restructured its July 2007 collaboration with Merck, Sharpe & Dohme Corp. ("Merck") for the development, manufacture and commercialization of ridaforolimus - ARIA's investigational mTOR inhibitor."